Literature DB >> 24462930

Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia.

Nikolay Mayanskiy1, Natalia Alyabieva2, Olga Ponomarenko2, Anna Lazareva2, Lubovj Katosova2, Alexander Ivanenko3, Tatiana Kulichenko2, Leila Namazova-Baranova2, Alexander Baranov2.   

Abstract

BACKGROUND: Pneumococcal infections remain a major medical problem associated with high morbidity and mortality. Moreover, the resistance of Streptococcus pneumoniae to conventional antibiotics is constantly growing. The implementation of pneumococcal conjugate vaccines (PCVs) in the last decade has dramatically reduced the incidence of the vaccine type-associated invasive pneumococcal diseases in many countries. However, information on the seroepidemiology of S. pneumoniae in Russia is limited.
METHODS: We report the results of serotyping and antibiotic susceptibility testing performed on 863 non-invasive pneumococcal isolates collected prospectively in 2009-2013 from children (median age 3.5 years) who sought medical care at five pediatric hospitals in Moscow. The isolates were recovered from the nasopharynx (71.2%), middle ear fluid (14.3%), and lower respiratory tract specimens (13.6%).
RESULTS: In total, we identified 45 different serotypes. The six leading serotypes (prevalence >5%) included 19F (21.7%), 6B (12.8%), 23F (10.1%), 14 (9.0%), 6A (8.4%), and 3 (7.5%). Serotype 19A isolates had a prevalence of 2.3%. The proportion of PCV-13 serotypes was 78%; the coverage by PCV-7 was 58.2% and was similar to that of PCV-10 (59.8%). The rate of multidrug-resistant pneumococci (i.e., resistant to ≥3 antimicrobials) was 22%. The majority of the multidrug-resistant isolates were serotype 6B, 14, 19A, and 19F. Penicillin non-susceptibility was displayed by 28% of the isolates. The resistance rate to erythromycin was 26%. Among the examined erythromycin-resistant strains, 54% had the erm(B) gene and 13% had the mef gene as a single resistance determinant, whereas both determinants were found in 31% of these strains.
CONCLUSIONS: Our data predict a good coverage of the circulating S. pneumoniae by the PCVs and could be useful for evaluating the serotype distribution in support of the introduction of PCV in Russia. In addition, the antimicrobial resistance rate of S. pneumoniae in Russia is substantial, and the emergence of pneumococcal strains with a dual macrolide resistance mechanism is alarming.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Children; Pneumococcal conjugate vaccine; Serotype; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2014        PMID: 24462930     DOI: 10.1016/j.ijid.2013.11.005

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  19 in total

1.  Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic Tolerance.

Authors:  Raymond N Allan; Samantha Morgan; Sanjita Brito-Mutunayagam; Paul Skipp; Martin Feelisch; Stephen M Hayes; William Hellier; Stuart C Clarke; Paul Stoodley; Andrea Burgess; Hasnaa Ismail-Koch; Rami J Salib; Jeremy S Webb; Saul N Faust; Luanne Hall-Stoodley
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Pediatric Invasive Pneumococcal Disease (IPD) in Yogyakarta, Indonesia: A Case Series.

Authors:  Eggi Arguni; Conroy Surya Wijaya; Ratni Indrawanti; Ida Safitri Laksono; Naruhiko Ishiwada
Journal:  Glob Pediatr Health       Date:  2022-06-27

Review 3.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

4.  One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-vaccine era.

Authors:  Gulnihan Ustundag; Eda Karadag-Oncel; Sebahat Sen-Tas; Ahu Kara-Aksay; Dilek Yilmaz-Ciftdogan; Nisel Yilmaz; Mehmet Ceyhan
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

5.  Microbiological and Susceptibility Profile of Clinical Gram Positive Isolates at a Tertiary Pediatric and Maternity Hospital in Ulaanbaatar, Mongolia.

Authors:  Susanna Felsenstein; Sarantsetseg Bira; Narangerel Altanmircheg; Enkhtur Shonkhuuz; Ariuntuya Ochirpurev; David Warburton
Journal:  Cent Asian J Glob Health       Date:  2019-09-30

6.  Antimicrobial resistance, penicillin-binding protein sequences, and pilus islet carriage in relation to clonal evolution of Streptococcus pneumoniae serotype 19A in Russia, 2002-2013.

Authors:  N Mayanskiy; T Savinova; N Alyabieva; O Ponomarenko; E Brzhozovskaya; A Lazareva; L Katosova; R Kozlov
Journal:  Epidemiol Infect       Date:  2017-03-20       Impact factor: 4.434

7.  Representation of Streptococcus Pneumoniae in Outpatient Population of Sarajevo Canton.

Authors:  Mufida Aljicevic; Emina Karcic; Sabaheta Bektas; Bekir Karcic
Journal:  Med Arch       Date:  2015-06-10

8.  Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013.

Authors:  Songyin Huang; Xiaoqiang Liu; Weisi Lao; Suhua Zeng; Huiqi Liang; Rihui Zhong; Xinlu Dai; Xiquan Wu; Hongyu Li; Yandan Yao
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

9.  Antibiotic resistance of Streptococcus pneumoniae, isolated from nasopharynx of preschool children with acute respiratory tract infection in Lithuania.

Authors:  Indrė Stacevičienė; Sigita Petraitienė; Daiva Vaičiūnienė; Tomas Alasevičius; Jūratė Kirslienė; Vytautas Usonis
Journal:  BMC Infect Dis       Date:  2016-05-20       Impact factor: 3.090

10.  Characteristics of serogroup 20 S.pneumoniae isolates from Brazil.

Authors:  Juliana Caierão; Fernando Hayashi Sant'Anna; Paulina Hawkins; Gabriela Rosa Cunha; Mariana Mott; Diego Rodrigues Falci; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  BMC Infect Dis       Date:  2016-08-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.